Drugs / F-DCFPyL Injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT03495427 | Dec 2019 → Feb 2029 expected | prostate carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | F-DCFPyL Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03495427 ↗ |
| Modality | Diagnostic / imaging agent | “F-DCFPyL Injection is a radioactive diagnostic imaging agent” NCT03495427 ↗ |
| Route | Intravenous | “via an in-dwelling catheter placed in an antecubital vein or an equivalent venous access.” NCT03495427 ↗ |